Immunotherapy plus radiation may fight metastatic colon cancer
NCT ID NCT02437071
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether adding the immunotherapy drug pembrolizumab to standard radiation or ablation could help people with metastatic colorectal cancer. The idea is that the combination might trigger a stronger immune response that also attacks tumors not directly treated. The trial enrolled 34 adults who had already tried at least two standard treatments. Researchers measured how many patients saw their tumors shrink and tracked side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pembrolizumab (an immunotherapy drug) plus radiation therapy or radiofrequency ablation
What this could lead to
If it works, this could offer a new treatment option for people with advanced colorectal cancer who have run out of standard therapies.
What could go wrong
This is a small, early-phase study with only 34 participants, so results may not apply to everyone. The combination may cause side effects and may not shrink tumors as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States